Latest Medtech News
From organ preservation and AI-powered MSK care to autonomous imaging, respiratory monitoring and ultrasound BCI, this week’s MedTech funding activity highlights strong investor interest in technologies targeting clinical efficiency, earlier diagnosis and more accessible care. Read more below.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Bridge to Life raises $110M to scale VitaSmart perfusion system across US transplant centers
Bridge to Life has raised $110M in Series C and debt financing, led by Soleus Capital with participation from Lauxera Capital Partners, to accelerate the U.S. commercial rollout of its FDA-cleared VitaSmart™ HOPE System for liver transplantation. The funding will expand its commercial reach, advance a new organ viability assessment tool, and support the development of its multi-organ preservation pipeline.
President and CEO Don Webber: “This financing marks an important milestone for Bridge to Life and reflects the confidence our investors have in our technology, team, and long-term growth strategy."
Flagler Health raises $50M Series B to scale AI-powered MSK platform
Flagler Health has raised $50M in Series B funding, led by Bessemer Venture Partners, bringing total funding to $63M. The company’s AI-native platform integrates with existing EMRs to streamline musculoskeletal care, from triage to billing and patient communications. The funding will support further expansion across U.S. MSK practices.
CEO Albert Katz: “MSK is where the healthcare system's dysfunction is most visible,”
Versa Vascular expands Series C to $42M
Versa Vascular has expanded its Series C financing by $15M, bringing the round to $42M. The funding will support clinical studies of its AdapTR™ transcatheter tricuspid repair device, including a U.S. Early Feasibility Study, as well as further product development and optimization. The company also appointed Bill Shields as CEO, following his 15 years at Medtronic’s structural heart business.
CEO Bill Shields: “I am thrilled to join Versa Vascular at a time when we are seeing positive results clinically, close to expanding our clinical work to the U.S., and receiving continued investor confidence,”
Maculaser closes €4.4M round to push retinal laser therapy into clinical studies
Wellinks secured $10M to scale its FDA-cleared Spire RPM platform, which uses wearable technology to monitor respiratory health and support earlier intervention for chronic conditions. Funds will drive commercial expansion, clinical data growth, and broader cardiopulmonary applications.
CEO Jani Tirronen
Ayati Devices raises ₹15 Crore in Pre-Series A funding
Ayati Devices has raised ₹15 crore in Pre-Series A funding led by Inflexor Ventures. The funding will support commercialization of its diagnostic technologies for diabetic foot complications, including Angiocam, while expanding manufacturing, R&D and global market reach.
Founder and CEO Nishant Kathpal stated the investment is a crucial milestone in making advanced diagnostics more accessible.
Futong Huizhi raises tens of millions of yuan to advance ultrasound BCI
Chinese MedTech company Futong Huizhi has raised tens of millions of yuan in an angel round led by Vision+ Capital, with participation from Yosen AI. The funding will support R&D of its tFUS-Mind closed-loop ultrasound brain-computer interface, clinical trials, team expansion and sales development.
Founder and Chairman Dr. Chen Jiangang
Henry Ford + MSU Innovation Fund makes first investments
The Henry Ford + MSU Innovation Fund has made its first investments in LightHearted AI and M3D, supporting technologies for heart valve disease detection and real-time radiation imaging. The healthcare-focused fund, launched with an initial $10M commitment, will provide capital and strategic support to help early-stage companies advance clinical validation and commercialization.
Co-Founder and CEO of M3D Mike Hopkins: “Henry Ford Health brings the clinical perspective that’s essential for translating innovative technologies into everyday practice,”
Co-Founder and CEO of LightHearted AI Lucrezia Cester
